Mobile

An Open Label, Randomized, Phase I/II Study of DMXAA in Combination with Carboplatin and Paclitaxel in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-004340-42

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Determination of the safety, tolerability and efficacy of DMXAA in combination with carboplatin and paclitaxel in patients with locally advanced and metastatic (Stage IIIb and IV) NSCLC

Critère d'inclusion

  • Patients with histologically confirmed locally advanced or metastatic NSCLC (Stage IIIb/IV) without prior chemotherapy will be included,Patients must have at least one unidimensionally measurable lesion according to the RECIST criteria. CNS metastases, major surgery, chemotherapy or radiation therapy excluded in the previous 4 weeks are exclusion criteria

Liens